Notably, truncating mutations of beta-2-microglobulin (B2M) were strongly associated with the nodular sclerosis subtype and younger age at diagnosis [70]; however it remains controversial whether disruption of B2M/MHC class I expression leads to a better clinical outcome [70,72]. This evidence concerns the gene B2M and Hodgkins lymphoma.